FDA Flashcards
NDA
New Drug Application
Center for Drug Evaluation
CDER
CTA
Clinical Trial Application
Essential for obtaining approval to conduct trials
BLA
Biologics license Application to FDA or EMA
GMP
Good manufacturing processes
Center for Biologics Evaluation & Research
CBER
Stages of Development
Preclinical
Clinical Trials Phases 1,2,3
ICH
International Council for Harmonization of Technical Requirements
Drug safety
Quality
Efficacy
Multinational
Risk management
EMA
EUROPEAN medicinal Agency
IND
Investigational new drug
RMP
Risk Management Plan
CTA
Clinical Trial Application
Outside of USA
Phase 1
First in Human
Evaluate safety and dosage in a small group
Phase 2
Proof of concept
Dose range finding
Efficacy and side effects with targeted condition
Phase 3
Large scale testing of effectiveness and long term side effects
Phase 4
Post marketing studies post approval
EPAR
European Public Accessment Report
CNS
Central Nervous System
EU CTR
European Clinical Trial Regulation
eCTD
Electronic common technical document
MAA
Marketing Authorization
Application internationally
Fast Track
Breakthrough
Accelerated Approval
Priority Review
FDA Accerlated Approval
Break through
Any Drug developed to treat a with unmet needs.
Or Drug needs to show advantage of current offering
Orphan Drug
A rare disease, less than 10,000 people affected.
In USA 200,000
ICF
Informed Consent Form for patients within study-
Wave 2
2nd batch of Countries for submissions
IB
Investigator brochure
IMPD
Investigational Medicinal Product Dossier
PMR
Post Marketing Requirements
Chemistry Manufacturing Controls
CMC
Cancer Drug approval Process
Early Phase
Late Phase
FDA Review of NDA
CRO
Clinical Research Organization
eDMS
Electrónic Data Management System
Veeva
CRO
Contract Research Organization
SAP
Statistical Analysis Plan